TROPION-Lung04: Dato-DXd Plus Immunotherapy in Advanced NSCLC

EP: 1.First-Line Treatment Strategies for Advanced Non–Small Cell Lung Cancer

EP: 2.The Role of CTLA-4 Inhibitors in NSCLC

EP: 3.NSCLC: PD-L1 Expression and Treatment Decision-Making

EP: 4.TROPION-Lung01: Dato-DXd in Previously Treated Advanced NSCLC

EP: 5.Expert Perspectives on the Results of the TROPION-Lung01 Study in NSCLC

EP: 6.EVOKE-02: Sacituzumab Govitecan Plus Pembrolizumab in Advanced NSCLC

Now Viewing

EP: 7.TROPION-Lung04: Dato-DXd Plus Immunotherapy in Advanced NSCLC

EP: 8.A Role for Biomarkers in Selecting Appropriate Patients for ADCs in NSCLC

EP: 9.First-Line Treatment for EGFR-Mutant Advanced Lung Cancer

EP: 10.FLAURA2: Osimertinib and Chemotherapy in Frontline EGFR-Mutant NSCLC

EP: 11.MARIPOSA: Amivantamab and Lazertinib in Frontline EGFR-Mutant NSCLC

EP: 12.Treatment Options in EGFR-Mutant NSCLC in Second Line and Beyond

EP: 13.MARIPOSA-2: Amivantamab and Chemotherapy in EGFR-Mutant NSCLC in Second Line and Beyond

EP: 14.Antibody-Drug Conjugates in EGFR-Mutant NSCLC

EP: 15.Clinical Pearls and Future Perspectives in Advanced NSCLC

This is a synopsis of a Peer Exchange video series featuring Benjamin P. Levy, MD, of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Solange Peters, MD, PhD, of University Hospital of Lausanne; Joshua K. Sabari, MD, of NYU Langone’s Perlmutter Cancer Center; Edward B. Garon, MD, MS, of UCLA Jonsson Comprehensive Cancer Center; and Marina Chiara Garassino, MD, of University of Chicago Medicine Comprehensive Cancer Center.

Dr Levy asks Dr Sabari to summarize results from the phase 1b TROPION-Lung04 study adding the ADC [antibody-drug conjugate] datopotamab deruxtecan to durvalumab with or without platinum chemotherapy in the first-line setting. Dr Sabari states the early data shows the combinations appear relatively safe and tolerable, though larger studies are needed before changing practice.

Dr Peters notes it remains unclear whether platinum chemotherapy adds benefit over the ADC-immunotherapy combination, with conflicting early data from different trials. She cautions about the risk of interstitial lung disease (ILD) with ADCs plus immunotherapy in the curative-intent frontline setting. Dr Levy agrees, stating his risk tolerance for ILD would be lower in PD-L1 high versus low/negative patients if it meant stopping pembrolizumab. In conclusion, the experts concur more data is needed to determine if ADCs plus immunotherapy can replace current platinum-based chemotherapy regimens in particular NSCLC patient subgroups.

*Video synopsis is AI-generated and reviewed by OncLive editorial staff.